IMVT Healthcare

Immunovant, Inc.

$29.04+2.22%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 6.0B USD
Enterprise value: 5.2B USD
Full-time employees: 315

Overall health

Not enough data: too little is reported yet for an overall view

Only 2 of 4 categories have enough reported data; an overall score needs at least 3.

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 58% from March 2023 to August 2026.
Immunovant had 58% more shares at August 2026 than at March 2023, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Immunovant had 58% more shares at August 2026 than at March 2023, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Immunovant looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
Immunovant reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

—

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-9.0%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-10.9%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-6.9%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield12.3%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.81

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -0.55Sector median: 0.6250 · MAD: 0.3380

Current ratio7.27×

SEC filings · latest balance sheetReported value33% base weight · Z-score 3.38Sector median: 2.5860 · MAD: 1.3850

Debt / equityUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Immunovant

Is Immunovant getting weaker?: Its latest SEC filing (Aug 6, 2026) showed no major changes.
How is Immunovant valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -9.0% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -9.0% vs peers 1.5% (weaker than 100% of peers).
Is Immunovant growing?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How profitable is Immunovant?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How risky is Immunovant?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 7.27× vs a peer median of 2.59× (stronger than 82% of peers).Current ratio 7.27× vs peers 2.59× (stronger than 82% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 6, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

	Previous quarter	Latest quarter	Change
Net income (12 months)	−505.6M USD	−538.2M USD	+6.4%
Free cash flow (12 months)	−407.3M USD	−414.3M USD	+1.7%
Cash	902.1M USD	797.8M USD	−11.6%
Shares outstanding	205.3M	206.6M	+0.6%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY Mar 2022	FY Mar 2023	FY Mar 2024	FY Mar 2025	FY Mar 2026	Change
Return on assets (ROA)	-30.4%	-52.0%	-38.9%	-53.3%	-52.8%	▲ 0.5 pts
Return on equity (ROE)	-33.4%	-58.2%	-42.0%	-58.5%	-59.3%	▼ 0.8 pts
Current ratio	11.52×	9.34×	13.70×	11.16×	9.09×	▼ 19%

IMVT price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Worth knowing

Shareholders being diluted. Shares outstanding up 58% from March 2023 to August 2026.

Immunovant had 58% more shares at August 2026 than at March 2023, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Immunovant had 58% more shares at August 2026 than at March 2023, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Immunovant looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

Immunovant reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about Immunovant

Is Immunovant getting weaker?

Its latest SEC filing (Aug 6, 2026) showed no major changes.

How is Immunovant valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -9.0% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -9.0% vs peers 1.5% (weaker than 100% of peers).

Is Immunovant growing?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How profitable is Immunovant?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How risky is Immunovant?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 7.27× vs a peer median of 2.59× (stronger than 82% of peers).Current ratio 7.27× vs peers 2.59× (stronger than 82% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Net income (12 months)

−505.6M USD

−538.2M USD

+6.4%

Free cash flow (12 months)

−407.3M USD

−414.3M USD

+1.7%

Cash

902.1M USD

797.8M USD

−11.6%

Shares outstanding

205.3M

206.6M

+0.6%

Key ratios

FY Mar 2022

FY Mar 2023

FY Mar 2024

FY Mar 2025

FY Mar 2026

Change

Return on assets (ROA)

-30.4%

-52.0%

-38.9%

-53.3%

-52.8%

▲ 0.5 pts

Return on equity (ROE)

-33.4%

-58.2%

-42.0%

-58.5%

-59.3%

▼ 0.8 pts

Current ratio

11.52×

9.34×

13.70×

11.16×

9.09×

▼ 19%